Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 258Radiotherapy 193Cetuximab 151pembrolizumab 123Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 78Radiotherapy, Intensity-Modulated 72Surveys and Questionnaires 46Nivolumab 42Drug Therapy 34Radiation 33Blood Specimen Collection 27Erlotinib Hydrochloride 26Gemcitabine 25Immunohistochemistry 22Gefitinib 22Cyclophosphamide 22Surgical Procedures, Operative 21Standard of Care 20durvalumab 19Pemetrexed 19Magnetic Resonance Spectroscopy 19Radiosurgery 17Capecitabine 17Chemotherapy, Adjuvant 16Celecoxib 16Biopsy 16atezolizumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × enfortumab vedotin × Head & Neck × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡